Safety and tolerability of azilsartan medoxomil in subjects with essential hypertension: a one-year, phase 3, open-label study
Clinical and experimental hypertension (New York, N.Y. : 1993), 2016, Pages 1-9.
Hypertensionangiotensin receptor blockerazilsartanchlorthalidonediureticMore(1+)
This 56-week phase 3, open-label, treat-to-target study, involving 2 consecutive, non-randomized cohorts, evaluated the safety and tolerability of azilsartan medoxomil (AZL-M) in essential hypertension (mean baseline blood pressure [BP] 152/100 mmHg). All subjects (n = 669) initiated AZL-M 40 mg QD, force-titrated to 80 mg QD at week 4, i...More
Full Text (Upload PDF)
PPT (Upload PPT)